Peritoneal Residual Volume Induces Variability of Ultrafiltration with Icodextrin

♦ Background: Icodextrin induces ultrafiltration (UF) during long-dwell exchanges by creating a difference in oncotic pressure between the peritoneal cavity and plasma; however, the mechanisms governing intra-patient and inter-patient variability in UF when icodextrin is used remain largely unexplained. In the present study, we show theoretically that differences in peritoneal residual volume (VR) have a more profound effect on UF with icodextrin use than with glucose use. This phenomenon is attributed to a differential effect of VR on oncotic, rather than osmotic, pressure between the peritoneal cavity and plasma. ♦ Methods: The three-pore model was used to calculate the effect on UF of VR between 150 mL and 1200 mL when 7.5% icodextrin (ICO) or 3.86% glucose solution is used at the end of a 12-hour dwell in the four patient transport groups (that is, fast to slow). Oncotic (with ICO) and osmotic (with glucose) pressure differences averaged over the entire dwell were also calculated. ♦ Results: As expected, at a nominal VR of 300 mL, UF with glucose differed substantially between the four patient transport groups (2 - 804 mL), whereas UF with ICO did not (556 - 573 mL). When VR was increased to 1200 mL from 150 mL, the concentrations of the oncotic and osmotic agents at the start of the dwell with an infusion volume of 2 L decreased to 4.9% from 7.0% with ICO and to 2.5% from 3.6% with glucose. The decrease in UF on average was greater with ICO [to 252 mL from 624 mL: that is, a reduction of 372 mL (60%)] than with glucose [to 292 mL from 398 mL: that is, a reduction of 106 mL (27%)]. Those trends agreed with the calculated reductions in the oncotic pressure difference with ICO [reduction of 12 mmHg (49%)] and the osmotic pressure difference with glucose [reduction of 19 mmHg (33%)]. ♦ Conclusions: When ICO is used, VR modifies the oncotic pressure difference between the peritoneal cavity and plasma to substantially alter UF. This modification suggests that potential causes of increased VR should be considered when UF with ICO is considerably less than expected. Prospective clinical studies evaluating the relationship between VR and UF with ICO are warranted to validate the theoretical predictions in this report.

[1]  S. Prichard,et al.  RELATIONSHIP BETWEEN DRAIN VOLUME/FILL VOLUME RATIO AND CLINICAL OUTCOMES ASSOCIATED WITH OVERFILL COMPLAINTS IN PERITONEAL DIALYSIS PATIENTS , 2011, Peritoneal Dialysis International.

[2]  N. Chen,et al.  Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[3]  T. Stompór,et al.  Understanding the variability in Ultrafiltration Obtained with Icodextrin , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[4]  A. Dogan,et al.  Effects of Twice-Daily Icodextrin Administration on Blood Pressure and Left Ventricular Mass in Patients on Continuous Ambulatory Peritoneal Dialysis , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[5]  D. Oreopoulos,et al.  The Variability in Ultrafiltration Achieved with Icodextrin, Possibly Explained , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[6]  J. Waniewski,et al.  The kinetics of water transperitoneal transport during long-term peritoneal dialysis performed using icodextrin dialysis fluid. , 2009, Polskie Archiwum Medycyny Wewnetrznej.

[7]  S. Santacroce,et al.  The Utility of Two Daytime Icodextrin Exchanges to Reduce Dextrose Exposure in Automated Peritoneal Dialysis Patients: A Pilot Study of Nine Patients , 2008, Blood Purification.

[8]  A. Werynski,et al.  Combination of Crystalloid (Glucose) and Colloid (Icodextrin) Osmotic Agents Markedly Enhances Peritoneal Fluid and Solute Transport during the Long PD Dwell , 2007, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[9]  J. Bargman,et al.  Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis , 2007, International Urology and Nephrology.

[10]  S. Mujais,et al.  Glucose sparing in peritoneal dialysis: implications and metrics. , 2006, Kidney international. Supplement.

[11]  S. Davies Exploring new evidence of the clinical benefits of icodextrin solutions. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  E. Vonesh,et al.  Modeling of Icodextrin in PD Adequest® 2.0 , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[13]  I. Karayaylali,et al.  What is the Optimal Dwell Time for Maximizing Ultrafiltration with Icodextrin Exchange in Automated Peritoneal Dialysis Patients? , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[14]  P. Durand APD schedules and clinical results. , 2003, Contributions to nephrology.

[15]  A. Werynski,et al.  Determination of High and Low Molecular Weight Molecules of Icodextrin in Plasma and Dialysate, Using Gel Filtration Chromatography, in Peritoneal Dialysis Patients , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[16]  S. Mujais,et al.  Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. , 2005, Journal of the American Society of Nephrology : JASN.

[17]  N. Yorioka,et al.  Peritoneal Ultrafiltration and Serum Icodextrin Concentration during Dialysis with 7.5% Icodextrin Solution in Japanese Patients , 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[18]  A. R. Morton,et al.  A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  U. Bahner,et al.  Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  B. Rippe,et al.  Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. , 2000, Kidney international.

[21]  P. Cavalli,et al.  Ultrafiltration with icodextrins in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. , 2000, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[22]  E. Vonesh,et al.  A Multinational Clinical Validation Study of Pd Adequest 2.0 , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[23]  G. Woodrow,et al.  Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  B. Lindholm,et al.  High peritoneal residual volume decreases the efficiency of peritoneal dialysis. , 1999, Kidney international.

[25]  A. Donker,et al.  Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  N. Schouten,et al.  Peritoneal transport characteristics with glucose polymer based dialysate. , 1996, Kidney international.

[27]  J. Brandes,et al.  Optimization of dialysate flow and mass transfer during automated peritoneal dialysis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  M. Raftery,et al.  A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. , 1994, Kidney international.

[29]  D. Struijk,et al.  Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. , 1993, Kidney international.

[30]  J. Waniewski,et al.  A quantitative description of solute and fluid transport during peritoneal dialysis. , 1992, Kidney international.